ATHA
Athira Pharma, Inc.
Latest Form 4:Sale$11KbySan Martin Javier (CHIEF MEDICAL OFFICER) · filed Jan 5, 2026
Athira Pharma, Inc. (ATHA) has 6 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jan 5, 2026.
- Industry:Biotechnology
- CEO:Mark J. Litton
- Employees:26
- HQ:Bothell, WA, US
- IPO:2020-09-18
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$43K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
San Martin JavierFirst filing | CHIEF MEDICAL OFFICER | Sale | 1,644 | $11K | Jan 5 | SEC ↗ |
Worthington MarkFirst filing | General Counsel and CCO | Sale | 876 | $6K | Jan 5 | SEC ↗ |
Litton Mark JamesFirst filing | President and CEO | Sale | 2,586 | $18K | Jan 5 | SEC ↗ |
CHURCH KEVINFirst filing | CHIEF SCIENTIFIC OFFICER | Sale | 876 | $6K | Jan 5 | SEC ↗ |
Renninger RobertFirst filing | Chief Financial Officer | Sale | 297 | $2K | Jan 5 | SEC ↗ |